The French biotechnology company Valneva stated that preliminary studies developed by her vaccine showed effectiveness against the Omicron strain of coronavirus. This is reported on the company’s website.
According to Valneva’s statement, three doses of its vaccine neutralize Omicron strain. Thus, during the first phase of the test of the drug VLA2001-201 serum 30 studies of the study were used to analyze the neutralization of the SARS-COV-2 original virus, as well as delta options and Omicron.
All samples presented neutralizing antibodies against the generic virus and Delta strain, and 87% of them presented neutralizing antibodies against Oomikron.
Valneva vaccine is different from other things that uses the inactivated COVID-19 virus entirely, and not just a spike protein. For this reason, some scientists have expected Valneva better to resist various virus strains. “We still see the value of Valneva vaccine in the fight against COVID-19, but its place in the vaccine market is now much less clear,” said Analyst Stifel Max Herrmann.
Earlier it was reported that the Indian Pharmaceutical Company Gennova Biopharmaceuticals will create a vaccine from the Omicron strain of coronavirus infection. It is assumed that it will be ready in one or two months. After short testing, the drug can be used as a third booster dose of the vaccine from COVID-19. The first phases of the drug testing took place at the end of 2021.